Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081538 | 0.94 | ALDH1A1 (0.40) | ALDH1A1MAPTHTTGAACASP6 | |
| SCHEMBL6080111 | 0.79 | MEN1 (0.36) | ALDH1A1MAPTHTTKMT2AGAA | |
| SCHEMBL3207826 | 0.78 | MEN1 (0.37) | ALDH1A1MAPTHTTKMT2AGAA | |
| SCHEMBL9705616 | 0.74 | MEN1 (0.45) | ALDH1A1MAPTHTTKMT2AGAA | |
| Ethane SCHEMBL20528153 | 0.72 | MEN1 (0.44) | ALDH1A1MAPTHTTKMT2AGAA | |
| SCHEMBL6081135 | 0.72 | HPGD (0.36) | ALDH1A1MAPTHTTKMT2AGAA | |
| SCHEMBL6986350 | 0.70 | ALDH1A1 (0.37) | ALDH1A1MAPTKMT2AGAAPOLB | |
| SCHEMBL18458829 | 0.70 | ALDH1A1 (0.50) | ALDH1A1MAPTHTTKMT2AGAA | |
| SCHEMBL31074909 | 0.69 | MEN1 (0.41) | ALDH1A1MAPTHTTKMT2AGAA | |
| SCHEMBL3975055 | 0.69 | ALDH1A1 (0.42) | ALDH1A1MAPTHTTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023096850-A1 | PHOSPHOINOSITIDE 3 KINASE GAMMA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096850-A1 | PHOSPHOINOSITIDE 3 KINASE GAMMA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | SCHERING AKTIENGESELLSCHAFT | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079503-A1 | Thiazolidinones and the use therof as polo-like kinase inhibitors | PLK4, PLK2, PLK3 | SMYD3 4022/4885ALDH1A1 2553/4885MAPT 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.